‌

US Patent 12104178 DHFR tunable protein regulation

Patent 12104178 was granted and assigned to Obsidian Therapeutics on October, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Current Assignee

Obsidian Therapeutics

Date Filed

December 28, 2021

Date of Patent

October 1, 2024

Patent Applicant

Obsidian Therapeutics

Patent Application Number

17646212

Patent Citations

‌

US Patent 7579439 Modulation of IL-2- and IL-15-mediated T cell responses

‌

US Patent 7625553 Method of treating cancer by administering an epithelum-derived T-cell factor

‌

US Patent 7834152 Antagonists of interleukin-15

‌

US Patent 7947265 Fusion proteins and methods for modulation of immune response

‌

US Patent 7998736 Adoptive immunotherapy with enhanced T lymphocyte survival

‌

US Patent 8026097 Expansion of NK cells and therapeutic uses thereof

‌

US Patent 8124084 Compositions and methods for immunomodulation in an organism using IL-15 and soluble IL-15Ra

‌

US Patent 8163879 Fusion molecules and IL-15 variants

‌

US Patent 8173792 Method for regulating protein function in cells using synthetic small molecules

‌

US Patent 8492118 Fusion molecules and IL-15 variants

•••

Patent Inventor Names

Dan Jun Li

Dexue Sun

Byron Delabarre

Brian Dolinski

Grace Y. Olinger

Mara Christine Inniss

Vipin Suri

Vijaya Balakrishnan

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

12104178

Patent Primary Examiner

CPC Code

Find more entities like US Patent 12104178 DHFR tunable protein regulation

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API